Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 72-year-old man is evaluated in the primary care clinic to discuss stroke prevention. He was recently diagnosed with nonvalvular atrial fibrillation after presenting with intermittent palpitations. He has a history of hypertension, benign prostatic hyperplasia, and osteoarthritis. Current medications include lisinopril, tamsulosin, and acetaminophen as needed. His heart rate is currently 78/min and regular. After a shared decision-making discussion regarding his CHA2DS2-VASc score and bleeding risks, the physician decides to initiate rivaroxaban.

Which of the following laboratory evaluations are essential for baseline assessment and routine ongoing monitoring of this specific pharmacotherapy? (Select all that apply)

  1. Serum creatinine to estimate creatinine clearanceAnswer
  2. Complete blood countAnswer
  3. C
    Prothrombin time and International Normalized Ratio (INR)
  4. D
    Activated partial thromboplastin time (aPTT)
  5. E
    Routine anti-factor Xa activity assays

Answer

The essential parameters for routine monitoring of rivaroxaban therapy are serum creatinine (to estimate creatinine clearance) and a complete blood count.
Rivaroxaban is a direct factor Xa inhibitor. Because it is partially cleared by the kidneys, patients must have their serum creatinine and calculated creatinine clearance evaluated at baseline and periodically (at least annually) to detect renal decline, which would necessitate dose adjustment or discontinuation to prevent bleeding. Additionally, a baseline and periodic complete blood count is essential to monitor for anemia secondary to occult gastrointestinal or genitourinary bleeding, a known risk of any anticoagulant.

Step-by-Step Solution

1
Identify the initiated pharmacotherapy and its mechanism of action.
The patient is starting rivaroxaban, which is a direct oral anticoagulant (DOAC) that inhibits factor Xa.
Understanding the drug class is necessary to determine appropriate monitoring parameters and distinguish them from older anticoagulants.
2
Determine the baseline and ongoing monitoring requirements for DOACs.
DOACs require baseline and periodic assessment of renal function (creatinine clearance) and a complete blood count. Liver function tests are also typically checked at baseline.
DOACs undergo renal clearance, meaning declining kidney function can lead to drug accumulation and increased bleeding risk. A CBC helps monitor for occult bleeding.
3
Evaluate the need for routine coagulation monitoring.
Unlike warfarin or unfractionated heparin, DOACs have predictable pharmacokinetics and do not require routine therapeutic drug monitoring with INR, aPTT, or anti-factor Xa assays.
Routine coagulation testing does not improve safety or efficacy for patients on DOACs and can lead to unnecessary clinical interventions.

Key Concept

Monitoring parameters for Direct Oral Anticoagulants (DOACs)
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic